Loading...

DNTH DIANTHUS THERAPEUTICS INC US FDA Inspections 8-K Filing

DNTH

DNTH

DIANTHUS THERAPEUTICS INC

(DNTH)

2026 8-K

Financial Results Report

FDA Approval Updates

Stock Offering Agreement

Financial Results Update

Financial Update

Financial Results Announcement

Corporate Update

License Agreement Signed

Funding Agreement

Positive Trial Results

Financial Statements

Financial Statements

Financial Results

Corporate Update

Financial Results

Management Appointment

Earnings Reports

Annual Meeting of Stockholders

Earnings Reports

Earnings Reports

Private Placement

Financial Results Disclosure

Reverse Stock Split and Rev...

Earnings Reports

Appointment of New Independ...

Merger and Name Change

Departure of Directors or C...

Merger Agreement

Termination of Sublease Agr...

Stockholder Rights Plan

Financial Condition and Res...

Delisting Notice

External Links:

Dianthus Therapeutics, Inc. filed an 8-K on March 26, 2026, reporting changes approved by the FDA for clinical trials of claseprubart, including the removal of ANA testing and reclassification of autoimmune safety risks, with no cases of lupus reported.

AI Assistant

DIANTHUS THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.